CN104643071B - Health product capable of relieving fatigue - Google Patents
Health product capable of relieving fatigue Download PDFInfo
- Publication number
- CN104643071B CN104643071B CN201510059582.5A CN201510059582A CN104643071B CN 104643071 B CN104643071 B CN 104643071B CN 201510059582 A CN201510059582 A CN 201510059582A CN 104643071 B CN104643071 B CN 104643071B
- Authority
- CN
- China
- Prior art keywords
- parts
- health product
- fatigue
- blood
- kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000036541 health Effects 0.000 title claims abstract description 55
- 239000003814 drug Substances 0.000 claims abstract description 37
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 19
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 19
- 235000008434 ginseng Nutrition 0.000 claims abstract description 19
- 241000208340 Araliaceae Species 0.000 claims abstract 6
- 239000009636 Huang Qi Substances 0.000 claims description 14
- 239000008280 blood Substances 0.000 abstract description 20
- 210000004369 blood Anatomy 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 13
- 210000004185 liver Anatomy 0.000 abstract description 10
- 210000003734 kidney Anatomy 0.000 abstract description 8
- 210000000952 spleen Anatomy 0.000 abstract description 4
- 210000002784 stomach Anatomy 0.000 abstract description 3
- 230000008506 pathogenesis Effects 0.000 abstract description 2
- 230000003014 reinforcing effect Effects 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract 4
- 241000045403 Astragalus propinquus Species 0.000 abstract 3
- 240000006079 Schisandra chinensis Species 0.000 abstract 3
- 235000006533 astragalus Nutrition 0.000 abstract 3
- 244000241838 Lycium barbarum Species 0.000 abstract 2
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 2
- 235000015468 Lycium chinense Nutrition 0.000 abstract 2
- 244000046146 Pueraria lobata Species 0.000 abstract 2
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 230000003044 adaptive effect Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 239000000047 product Substances 0.000 description 45
- 206010016256 fatigue Diseases 0.000 description 37
- 238000012360 testing method Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 230000009182 swimming Effects 0.000 description 15
- 240000005373 Panax quinquefolius Species 0.000 description 13
- 239000000284 extract Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000009874 shenqi Substances 0.000 description 11
- 229920002527 Glycogen Polymers 0.000 description 10
- 229940096919 glycogen Drugs 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000002440 hepatic effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 102100026189 Beta-galactosidase Human genes 0.000 description 6
- 108010059881 Lactase Proteins 0.000 description 6
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 108010005774 beta-Galactosidase Proteins 0.000 description 6
- 229940116108 lactase Drugs 0.000 description 6
- 239000012567 medical material Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- FSEUPUDHEBLWJY-HWKANZROSA-N diacetylmonoxime Chemical compound CC(=O)C(\C)=N\O FSEUPUDHEBLWJY-HWKANZROSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a health product capable of relieving fatigue. The healthcare product is prepared from the following traditional Chinese medicines in parts by weight: 3-15 parts of the root of kudzu vine, 3-12 parts of wolfberry fruits, 2-6 parts of fruits of Chinese magnoliavine, 1-3 parts of ginseng and 6-30 parts of astragalus membranaceus. According to the health product capable of relieving the fatigue, the selected medicines are not in paralleling with same kinds of medicines, are not in addition of the same medicine effects, and form a prescription with respect to the main etiology and pathogenesis for forming the fatigue. The schisandra chinensis is combined with the astragalus membranaceus and the ginseng in the prescription, so as to reach the effects of relieving the fatigue and improving the adaptive original shape; the root of kudzu vine is used for assisting the astragalus membranaceus in clearing yang of spleen and stomach; the wolfberry fruits are used for assisting the fruits of Chinese magnoliavine in reinforcing power for tonifying liver and kidney and boosting essence and blood; and the medication characteristics of complementing five organs and tonifying spleen and kidney are adopted, so that the health product is capable of playing a pivotal role, helping middle qi, tonifying liver and kidney and essence and blood, and fully playing a role in complementing the five organs.
Description
Technical field
The present invention relates to field of health care products, more particularly to a kind of health product of fatigue alleviating.
Background technology
Fatigability subhealth state becomes the major hidden danger for affecting the public healthy, World Health Organization (WHO)（WH0）One
Global prediction investigation shows that the people of true health only accounts for 5%, and the people for having disease accounts for 20%, and 75% people is then in subhealth state.
Population in subhealth state morbid state is in rising trend in many countries and regions, and Chinese adult fatigability subhealth state is about
For 30%.
Fatigue refers to that " organism physiology process can not continue its function in a certain specific level as a kind of physiological phenomenon
And/or can not maintain predetermined exercise intensity ".From the point of view of biochemistry angle, produce fatigue the reason for one be due to motion when
The peak power of energy system output declines；Two is can not to maintain fortune due to muscle strength decline or internal organs function reduction
Fatigue resistance.Fatigue occur after if cannot eliminate in time, it will gradually accumulate, ultimately result in the nerve of body, endocrine and
Immune system is not normal, or even organic disease occurs, becomes the key factor of destruction human physical and mental health.
Fatigue can be divided into physiologic fatigability and pathological fatigue.Physiologic fatigability can be by resting, sleep and nutrition
Dissolve by itself Deng conventional measure；And pathological fatigue is that by caused by disease, reason is more, performance is complicated, the morning and evening for going out
Different, degree weight is different, primary performance or cardinal symptom of some fatigue for disease, have for minor symptom.Its recover compared with
Slowly, the last symptom for disappearing mostly in disease-recovery processes, what is had even delays lifelong.So-called resisting fatigue, is exactly delay fatigue
Generation or the elimination that accelerates fatigue.
At present, the chemicalses of commercially available resisting fatigue such as amphetamine, modafinil, caffeine etc. occurs in delay fatigue
There is preferable effect with allaying tiredness aspect, but occur in that many untoward reaction, such as cardiovascular harmful effect, interference is slept
Dormancy, abalienation, additive etc..Therefore, the health product that exploitation is a kind of safely, effectively, have no toxic side effect are needed badly and carry out fatigue alleviating,
To meet the actual demand of people.
The content of the invention
It is an object of the invention to provide a kind of health product of safe and effective fatigue alleviating.
To realize the above-mentioned purpose of the present invention, the present invention provides a kind of health product of fatigue alleviating, is by following weight portion
Several Chinese medicine compositions：Radix Puerariae 3-15 parts, Fructus Lycii 3-12 parts, Fructus Schisandrae Chinensis 2-6 parts, Radix Ginseng 1-3 parts, Radix Astragali 6-30 parts.
The present invention also provides a kind of preparation technology of the health product of fatigue alleviating, and concrete technology is as follows.
（1）Extract：Above-mentioned medical material is taken by formula, coarse powder is ground into, by solvent of water three extractions are carried out.First time dosing
The water of 10 times of amounts of material, extracts 2 hours；Second plus the water of 8 times of amounts of medical material, extract 1.5 hours；6 times of amounts of third time plus medical material
Water, extracts 1 hour；Merge three extracting solution, be condensed into dry extract, be concentrated into proportion 1.3.
（2）Prepare：Radix Ginseng is used as medicine for former powder in formula, and mixes with the dry extract of other 4 taste medicines concentrations in side, in proportion
Icing Sugar is added, the Icing Sugar is 1 with the weight ratio of concentration thick paste:4, moistening is made with 75% ethanol, soft material processed is carried out with 12 mesh sieves
Granulation, 65 DEG C of drying, with 10 mesh and 60 mesh sieves granulate is carried out, and is obtained final product.
In the prescription of the present invention.
With Fructus Schisandrae Chinensis as monarch drug,《Sheng Nong's herbal classic》Point out that Fructus Schisandrae Chinensis sour in the mouth is warm in nature, be used with QI invigorating qi-restoratives, can treat
Impairment caused by overstrain weakness and emaciation.《Mingyi Bielu》Then think that it can lead foster the five internal organs；The famous doctor Zhang Jiegu clouds of Jin and Yuan dynasty：Fructus Schisandrae Chinensis, big benefit five
Visceral-qi.Eastern Han Dynasty's holy doctor Zhang Zhongjing once pointed out that Fructus Schisandrae Chinensis can be controlled " consumptive disease with deficient symptoms ".
Radix Ginseng, the Radix Astragali are ministerial drug, and Radix Ginseng strongly invigorating primordial QI, the Radix Astragali is the length of QI invigorating, and two medicines are shared with significant resisting fatigue
Effect.The Tang Dynasty, famous medical scholar's Sun Simiao was pointed out：May informal dress Fructus Schisandrae Chinensis, with tonifying five ZANG-organses gas.Meet between the moon in summer, the last month of summer, be stranded
Weary powerless, depletion of QI, with the Radix Astragali, ginseng compatibility, is made one spirit and is added with dynamic, and two sufficient biceps are gushed out.《Must be with book on Chinese herbal medicine》Assistant ginseng, stilbene,
Control summer tired.Two medicines assist monarch drug to strengthen the work(of QI invigorating qi-restoratives.Fructus Schisandrae Chinensis are help others ginseng, and to receive the lung gold of dissipation, then golden gas is hard
Solidifying, water source deep pool is thorough, and natural lung is sufficient and kidney is also sufficient.
Radix Puerariae, Fructus Lycii are adjuvant drug,《This Jing meets original》Think that Radix Puerariae rises category sun, the gas of clear sun in stomach can be inspired, assist
Radix Ginseng, the Radix Astragali strengthen the effect of tonification gastric qi；《Book on Chinese herbal medicine covers bamboo fish trap》Point out Fructus Lycii with " resistance to cold and summer-heat is lengthened the life.Add the solid marrow of essence, strong bone is strong
The work(of muscle ", mends impairment caused by overstrain especially.
Upper five kinds of Chinese medicine is shared, tonification liver heart spleen and lung kidney the five internal organs, again can Qi and Yijing, fatigue alleviating.This experimentation shows,
This side has the effect of obvious fatigue alleviating.
Modern society's life operating pressure causes greatly psychology to be constrained, and up to orderly and clearly, in addition modern's depression of liver-QI stays up late for a long time,
Excessive thinking, dark gas consumption blood consumes sad god, secretly consumes essence and blood, causes the sub-health states such as fatigue, hypomnesis.Western medicine is recognized
For subhealth state is the intermediateness between health and disease.Without corresponding record in TCM Document, but tired conduct
Common symptom in tcm clinical practice, be commonly described as in Chinese medical book " tired ", " exhausted ", " weary ", " asthenia ", " slack ", " tired ",
" powerless ", " weak ", " inability to raise the limbs " etc..
Our Fructus Schisandrae Chinensis are monarch drug, and Compatibility with Radix Astragali, Radix Ginseng then strengthen the effect of fatigue alleviating, improve the effect for adapting to former state,
Radix Puerariae helps Radix Astragali hair growth promoting taste positive clearly, and Fructus Lycii assists Fructus Schisandrae Chinensis to strengthen the power of invigorating the liver and kidney benefiting essence-blood.
Beneficial effects of the present invention compared with prior art.
The present invention provide fatigue alleviating health product, selected medicine neither similar medicine it is arranged side by side, nor identical medicine
The addition of effect, but the Etiological pathogenesis formed for fatigue carries out using drugs to form a prescription.The five internal organs are adopted in side and is mended, with spleen reinforcing kidney
Based on Medicinal Trait, can both assume personal Central Region, help middle gas, again can liver and kidney tonifying essence and blood, give full play to the effect of " the five internal organs are simultaneously mended ".
Specific embodiment
The present invention is further described with reference to specific embodiment.
Embodiment 1.
The present embodiment 1 provides a kind of health product of fatigue alleviating, is made up of the Chinese medicine of following parts by weight：Radix Puerariae 15
Part, 12 parts of Fructus Lycii, 2 parts of Fructus Schisandrae Chinensis, 3 parts of Radix Ginseng, 9 parts of the Radix Astragali.
The present invention also provides a kind of preparation technology of the health product of fatigue alleviating, and concrete technology is as follows.
（1）Extract：Above-mentioned medical material is taken by formula, coarse powder is ground into, by solvent of water three extractions are carried out.First time dosing
The water of 10 times of amounts of material, extracts 2 hours；Second plus the water of 8 times of amounts of medical material, extract 1.5 hours；6 times of amounts of third time plus medical material
Water, extracts 1 hour.Merge three extracting solution, be condensed into dry extract, be concentrated into proportion 1.3, thick paste weight 1097g.
（2）Prepare：Radix Ginseng is used as medicine for former powder in formula, and mixes with the dry extract of other 6 taste medicines concentrations in side, in proportion
Icing Sugar is added, the Icing Sugar is 1 with the weight ratio of concentration thick paste:4, moistening is made with 75% ethanol, soft material processed is carried out with 12 mesh sieves
Granulation, 65 DEG C of drying, with 10 mesh and 60 mesh sieves granulate is carried out.
To further illustrate beneficial effects of the present invention, the test case in clinical practice report presented below.
1st, experiment material.
1.1 animal：Kunming mouse, male mice body weight 18-22 gram, the long-living Bioisystech Co., Ltd in Liaoning provides,
Credit number：SCXK (the Liao Dynasty) 2013-0009.The long-living Bioisystech Co., Ltd in SD rats Liaoning provides, credit number：SCXK
(the Liao Dynasty) 2010-0001.
1.2 medicine：Test medicine（The health product of the present embodiment 1）, solvent for use is distilled water, takes gavage mode to be administered,
Gastric infusion volume 0.2ml/10g.Ke Laoke positive groups（Ke Laoke, Shenyang Yongda Pharmaceutical Co., Ltd., lot number 20131212,
2.25g for each person every day）；Ten simply SHENQI PIAN the positive group（Ten SHENQI PIAN simply, Jilin Pharmacy stock Co., Ltd, lot number
20131212,100ml for each person every day）.
1.3 reagent：Blood urea nitrogen（BUN）Testing cassete（Bioengineering Research Institute, lot number 20150518 are built up in Nanjing）, liver/flesh
Glycogen testing cassete（Lot number 20141123）, lactic acid（LD, lot number 20140920）Testing cassete（Survey serum, tissue etc.）, it is Nanjing
Build up Bioengineering Research Institute.
1.4 instrument：Animal balance, electronic balance, centrifuge, high speed disperser, boiling water bath, agitator, Plasma lactate instrument,
721 spectrophotometers, swimming trunk（50cm×50cm×40cm）, sheet lead, timer, hemoglobin pipet, sample injector, pipette,
Test tube, tool plug test tube.
2nd, experimental technique.
2.1 packets and dose design：6 groups of test point：Blank control group, the health product low dose group of the present embodiment 1（2g/
kg）, middle dose group（4g/kg）, high dose group（8g/kg）, Ke Laoke positive groups（Mice 0.09g/kg is equivalent to Ke Laoke liquid
16.7ml/kg, rat 0.045g/kg are equivalent to the ml/kg of Ke Laoke liquid 8.35）, ten simply SHENQI PIAN the positive group（Mice 0.6g/
Kg, rat 0.3g/kg）Adopt gavage（ig）Mode, 1 time/d, continuous 30d.
2.2 Loaned swimming test：Last is given after the health product 30min of the present embodiment 1, puts mice in swimming trunk went swimming,
The depth of water about 30cm, 25 DEG C ± 0.5 DEG C of water temperature, the sheet lead of the body weight of rat-tail root load 5%.Record mice starts to death from swimming
Time, as mice swimming time（min）.
2.3 serum urea nitrogen determinations：Diacetyl monoxime method.Male adult rat, last gives the health product of the present embodiment 1
After 30min, in the water went swimming 90min that temperature is 30 DEG C.Peace and quiet 60min dials eyeball blood sampling, 0.5ml after motion.In 4 DEG C of standings
After 3h, 5000r/min centrifugation 30min take serum and operate by kit specification, press examination and calculate serum urea nitrogen content：Urine
Plain nitrogen=A specimen/A standard × 20.0（mg/dl）.
2.4 hepatic glycogen are determined：Anthrone method.Male rat, last to 30min after sample, in the water tank middle reaches that temperature is 30 DEG C
Swimming 90min, peace and quiet 60min puts to death after motion, takes liver and is blotted with filter paper Jing after normal saline rinsing, accurately weighs liver
200mg, adds 4ml 5%TCA（Trichloroacetic acid）, 1min is homogenized, homogenate is poured into centrifuge tube, with 3000r/min centrifugations
15min, supernatant is transferred in another test tube.4ml TCA are added in precipitation, then 15min is centrifuged after being homogenized 1 minute, taken
Supernatant, the supernatant of centrifugation merges with first time, fully mixes.With anthrone method after 620nm wavelength colorimetric determinations, as the following formula
Calculate hepatic glycogen content：Hepatic glycogen（Mg/100g livers）=DU/DS×0.5V/G×100×0.9.Wherein, DU：Sample cell extinction
Degree；V：Extracting liquid volume；DS：Standard pipe absorbance；G：Hepatic tissue grams；0.5：Glucose in 0.5ml glucose standards
Content；0.9：Glucose is converted into into the coefficient of glycogen.
2.5 Plasma lactate：Male rat, last is added in 40ul rupture of membranes liquid to each blood sampling 20ul after sample 30min, and vibration is equal
It is even；Then 4% is born a heavy burden（Body weight）, stop after the water went swimming 10min that temperature is 30 DEG C, take a blood sample immediately 20ul, disposes 30min,
Take a blood sample again 20ul, and in adding 40ul rupture of membranes liquid, shaken well is determined with Plasma lactate instrument.After the motion of blood lactase acid elevation amplitude
The blood lactase acid value sampled immediately deducts the blood lactase acid value before motion and represents, the blood sampled immediately after the motion of blood lactate removal amplitude
Lactate deducts the blood lactase acid value of 30min after motion and represents.
2.6 statistical disposition：All data compare between two groups and adopt independent samples t-test by SPSS17.0 software processes, data
Represented using mean ± standard deviation, withP＜ 0.05 represents there is significant difference.
3 results.
3.1 are grouped at random according to Mouse Weight, and at the end of experiment, the weight ratio of each group mice is compared with difference is not notable, i.e. sample
Product are on the body weight increase of mice without impact.Concrete outcome is shown in Table 1.
Table 1：Impact of the test medicine to Mouse Weight（Mean ± standard deviation）.
| Group | Dosage g/kg | Number of cases/only | Original body mass/g | At the end of body weight/g |
| Blank control group | - | 14 | 18.92 ±0.20 | 37.94±3.97 |
| Ke Laoke positive groups | 0.09 | 14 | 18.86 ±0.53 | 39.95±4.84 |
| Ten simply SHENQI PIAN the positive group | 0.6 | 14 | 18.87 ±0.42 | 37.39±6.21 |
| Health product high dose group | 16 | 14 | 19.14±0.68 | 38.24±5.07 |
| Health product middle dose group | 8 | 14 | 18.89 ±0.65 | 37.95 ±6.42 |
| Health product low dose group | 4 | 14 | 18.90 ±0.63 | 38.23±4.89 |
Note：Compared with blank control group, *P＜ 0.05, * *P＜ 0.01, * * *P＜ 0.001.
The impact of 3.2 swimmings with a load attached to the body experiment.
Compare with blank control group, the mice trip of the basic, normal, high dosage group of the health product of the present embodiment 1 and the positive groups of Ke Laoke
The swimming time is obviously prolonged, significant difference；Ten simply the positive group swimming time of SHENQI PIAN also have prolongation, but there was no significant difference.
Show that the fatigue alleviating health product of the present embodiment 1 can improve the mice burden swimming time.The results are shown in Table 2.
Table 2：Impact of the test medicine to the mice burden swimming time（Mean ± standard deviation）.
| Group | Dosage g/kg | Number of cases/only | Swimming time/min |
| Blank control group | - | 20 | 112.50±38.62 |
| Ke Laoke positive groups | 0.09 | 20 | 251.95±51.43*** |
| Ten simply SHENQI PIAN the positive group | 0.6 | 20 | 140.05±58.35 |
| Health product high dose group | 16 | 17 | 218.12±72.14*** |
| Health product middle dose group | 8 | 12 | 194.82±45.86*** |
| Health product low dose group | 4 | 20 | 217.45±40.90*** |
Note：Compared with blank control group, *P＜ 0.05, * *P＜ 0.01.
3.3 serum urea nitrogen determinations.
Compare with blank control group, the health product middle dose group of the present embodiment 1, ten simply the positive group of SHENQI PIAN can significantly drop
Blood urea nitrogen is generated after harmonic motion；The health product high dose group of the present embodiment 1 also has obvious reduction to act on, but there was no significant difference.
Concrete outcome is shown in Table 3.
Table 3：Impact of the test medicine to serum urea nitrogen during rat motor（Mean ± standard deviation）.
| Group | Dosage g/kg | Number of cases/only | Serum urea nitrogen mmol/L |
| Blank control group | - | 12 | 8.33±6.40 |
| Ke Laoke positive groups | 0.045 | 10 | 7.69±2.29 |
| Ten simply SHENQI PIAN the positive group | 0.3 | 10 | 4.14±1.86** |
| Health product high dose group | 8 | 12 | 6.38±1.75 |
| Health product middle dose group | 4 | 10 | 4.87±0.79* |
| Health product low dose group | 2 | 10 | 8.51±2.23 |
Note：Compared with blank control group, *P＜ 0.05, * *P＜ 0.01.
3.4 hepatic glycogen are determined.
Compare with blank control group, each dosage group group hepatic glycogen is reduced, inconsistent with expected resultss, analysis reason is probably
Detection glycogen preparation sample time is slightly longer, causes glycogenolysis.
Table 4：Impact of the test medicine to rats'liver glycogen use amount（Mean ± standard deviation）.
| Group | Dosage g/kg | Number of cases/only | Hepatic glycogen mg/g |
| Blank control group | - | 16 | 18.47±10.85 |
| Ke Laoke positive groups | 0.045 | 16 | 11.62±7.11* |
| Ten simply SHENQI PIAN the positive group | 0.3 | 16 | 16.86±9.93 |
| Health product high dose group 1） | 8 | 16 | 9.97±5.76* |
| Health product middle dose group 2） | 4 | 16 | 16.08±6.69 |
| Health product low dose group 3） | 2 | 16 | 8.94±6.77* |
Note：Compared with blank control group, * P ＜ 0.05.
3.5 Plasma lactate.
Compare with blank control group, the health product low dose group of the present embodiment 1, middle dose group effect are not substantially or without effect；
The health product high dose group of the present embodiment 1 and Ke Laoke positive groups, the ten blood lactate removal amplitudes that simply the SHENQI PIAN positive is organized are bright
It is aobvious to increase；Show that the health product of the present embodiment 1 can promote the elimination of blood lactase acid after motion.Concrete outcome is shown in Table 5.
Table 5：Impact of the test medicine to blood lactate removal amplitude after rat motor（Mean ± standard deviation）.
| Group | Dosage g/kg | Number of cases/only | Blood lactase acid mmol/L |
| Blank control group | - | 12 | 5.65±2.07▲ |
| Ke Laoke positive groups | 0.045 | 12 | 10.48±1.72* |
| Ten simply SHENQI PIAN the positive group | 0.3 | 12 | 8.37±1.51*▲ |
| Health product high dose group 1） | 8 | 12 | 8.75±2.97*▲ |
| Health product middle dose group 2) | 4 | 12 | 7.98±2.25*▲ |
| Health product low dose group 3) | 2 | 12 | 6.90±1.29▲1） |
Note：Compared with blank control group, * P ＜ 0.05；Compared with model group,▲P ＜ 0.05；Each health product group is compared
,1）2）3）P ＜ 0.05.
4th, conclusion：Test result indicate that there is the health product of the present embodiment 1 anti-fatigue health-caring to act on.
5th, model case.
Case 1：Cui, female, 45 years old, civil servant.Feel fatigue and weak often over one year, faint low voice, spontaneous perspiration, food is received not
It is good, accidental abdominal distention, two is just uncomfortable, when send out oral ulcer, dreaming often and waking easily, sore waist and aching in the waist and the back, hands and feet being not warm etc., pale tongue with white fur, thready pulse
It is weak.Doctor trained in Western medicine is examined as " fatigue syndrome ".After the oral health product four weeks of the present embodiment 1, patient's weak sense mitigates, and spontaneous perspiration stops, drinks
Food is gradually good, and remaining symptom has improvement in various degree.After taking three months, above-mentioned symptom disappears substantially.
Case 2：Certain is shut out, man, 56 years old, government bodies cadre.Increase suddenly because of working strength within nearly one month, sense from head to foot without
Power, easily tired, absent minded, vexed, tinnitus, visual deterioration, foreign body sensation in the throat, palm is tacky.Red tongue, stringy and thready pulse.
The system parenchyma such as absent cardiovascular, endocrine sexually transmitted disease (STD) becomes.The trouble is " sub-health state ".Give the health product of the present embodiment 1 oral, while
Take a good rest.1 health product of the present embodiment are taken after one week, that is, is felt above-mentioned symptom and is clearly better, following the service one week, above-mentioned performance is basic
Disappear.
Case 3：Poplar, female, 37 years old.Puerperal day and night looks after baby, does not have enough sleep, and occurs constipation today, 2-3 day a line,
Neck shoulder stiffness, the vexed discomfort of stomach, shortness of breath and palpitation, dark and dim eyesight when standing up, get up in the morning unplessantness displeasure, sighing frequently, pale tongue with white fur, arteries and veins
It is weak.Jing is looked into, without organic disease.The smooth feelings will of patient is advised, diet is adjusted, is rested, while giving the health product of the present embodiment 1 oral more.Clothes
After with two weeks of the invention, take a favorable turn above-mentioned symptom more, still feel shoulder and carry on the back stiff, following the service January, above-mentioned performance disappears substantially.
Embodiment 2.
The present embodiment 2 provides a kind of health product of fatigue alleviating, is made up of the Chinese medicine of following parts by weight：Radix Puerariae 10
Part, 8 parts of Fructus Lycii, 3 parts of Fructus Schisandrae Chinensis, 2.5 parts of Radix Ginseng, 11 parts of the Radix Astragali.
Embodiment 3.
The present embodiment 3 provides a kind of health product of fatigue alleviating, is made up of the Chinese medicine of following parts by weight：Radix Puerariae 8
Part, 5 parts of Fructus Lycii, 4 parts of Fructus Schisandrae Chinensis, 1.5 parts of Radix Ginseng, 9 parts of the Radix Astragali.
Claims (4)
1. a kind of health product of fatigue alleviating, it is characterised in that be made up of the Chinese medicine of following parts by weight：Radix Puerariae 3-15
Part, Fructus Lycii 3-12 parts, Fructus Schisandrae Chinensis 2-6 parts, Radix Ginseng 1-3 parts, Radix Astragali 6-30 parts.
2. health product of fatigue alleviating as claimed in claim 1, it is characterised in that be made up of the Chinese medicine of following parts by weight
's：15 parts of Radix Puerariae, 12 parts of Fructus Lycii, 2 parts of Fructus Schisandrae Chinensis, 3 parts of Radix Ginseng, 9 parts of the Radix Astragali.
3. health product of fatigue alleviating as claimed in claim 1, it is characterised in that be made up of the Chinese medicine of following parts by weight
's：10 parts of Radix Puerariae, 8 parts of Fructus Lycii, 3 parts of Fructus Schisandrae Chinensis, 2.5 parts of Radix Ginseng, 11 parts of the Radix Astragali.
4. health product of fatigue alleviating as claimed in claim 1, it is characterised in that be made up of the Chinese medicine of following parts by weight
's：8 parts of Radix Puerariae, 5 parts of Fructus Lycii, 4 parts of Fructus Schisandrae Chinensis, 1.5 parts of Radix Ginseng, 9 parts of the Radix Astragali.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510059582.5A CN104643071B (en) | 2015-02-04 | 2015-02-04 | Health product capable of relieving fatigue |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510059582.5A CN104643071B (en) | 2015-02-04 | 2015-02-04 | Health product capable of relieving fatigue |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104643071A CN104643071A (en) | 2015-05-27 |
| CN104643071B true CN104643071B (en) | 2017-04-19 |
Family
ID=53235120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510059582.5A Active CN104643071B (en) | 2015-02-04 | 2015-02-04 | Health product capable of relieving fatigue |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104643071B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004100083A (en) * | 2002-09-09 | 2004-04-02 | Tasuku:Kk | Functional fabric |
| CN100396197C (en) * | 2005-04-06 | 2008-06-25 | 云南白药集团股份有限公司 | Health protection food for antifatigue and raising oxygen deficiency tolerance |
| CN103142760A (en) * | 2013-04-01 | 2013-06-12 | 通化百泉保健食品有限公司 | Ginseng Yangyuanbao tablet and preparation method thereof |
-
2015
- 2015-02-04 CN CN201510059582.5A patent/CN104643071B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104643071A (en) | 2015-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103735838A (en) | Healthcare medicinal liquor capable of nourishing and tonifying kidney and preparation method thereof | |
| CN109718303A (en) | Improving the skin maintenance and cosmetic benefits of female ovary function improves the Chinese medicine composition of female skin | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN104286864B (en) | A kind of semen astragali complanati oral liquid improving immunity and preparation method thereof | |
| CN102048913B (en) | Traditional Chinese medicine preparation for treating climacteric syndrome and preparation method thereof | |
| CN104643071B (en) | Health product capable of relieving fatigue | |
| CN108935694A (en) | A kind of healthcare goat milk powder and preparation method thereof with antifatigue simultaneous void of enriching blood | |
| CN101024010A (en) | Chinese medicine for invigorating Qi and tonifying kidney, and anti-sanility | |
| CN104491310B (en) | Anti-Fatigue Composition and its preparation method and application | |
| CN103495108B (en) | Medicine for treating chronic hypotension and preparation method for medicine | |
| CN102552677B (en) | Coptis chinensis and radix rehmanniae Anxiao capsule and preparation method thereof | |
| CN102824469A (en) | Detoxification traditional Chinese medicine and preparation method thereof | |
| CN102293985A (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN105343808A (en) | Traditional Chinese medicine composition with weight reducing effect and preparation method of traditional Chinese medicine composition | |
| CN109718305A (en) | Improve energy and blood of human body function and improves the Chinese medicine composition that resist oxygen lack delays senescence | |
| CN107737259A (en) | A kind of Chinese prescription for improving male's sexual | |
| CN108379367A (en) | Pure Chinese medicine drug of drug rehabilitation and preparation method thereof | |
| CN104258336B (en) | A kind of traditional Chinese powder medicine for application treatment senile hypertension | |
| CN110433270B (en) | Ice-removing traditional Chinese medicine | |
| CN101708230A (en) | Narcotic-abstaining medicine and preparation method thereof | |
| CN100400090C (en) | Medicine composition for treating myasthenia gravis and prepn. method therefor | |
| CN105943833A (en) | Anti-fatigue traditional-Chinese-medicine health-care tea for sports | |
| CN104958504A (en) | Traditional Chinese medicine composition for preventing and treating sub-health and preparation method of traditional Chinese medicine composition | |
| CN108785586A (en) | A kind of Chinese medicine composition and application for auxiliary treatment motor neuron disease | |
| CN104840872A (en) | Traditional Chinese medicine for treating stable angina pectoris of coronary heart disease complicated with diabetic hyperlipemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |